Women aged 35-54 years are making up an increasing proportion of acute MI hospitalizations, researchers reported at AHA 2018.

The drug—which currently has an indication for reducing cardiac death in addition to glycemic control—has a beneficial effect on LV mass.

The question remains if these results can be generalized to other populations, study discussant says.

Autopsy data from PDAY suggest faster and more dramatic disease progression in some individuals, with no clear link to traditional risk factors.

The barrage of economic analyses appears to have had an impact, given that the prices for PCSK9 inhibitors were lowered in 2018, says one expert.

Experts at VIVA 2018 discussed how the trial data could change practice and which patients will likely benefit.

In a special session at the AHA’s annual meeting in Chicago, researchers argued that violence should be considered a CV risk factor.

Investigators tracked nearly half of the original cohort, providing further support for CABG in diabetic patients with multivessel CAD.

While not necessary, experts argue that a hybrid OR is valuable in treating higher-risk patients with the necessary resources.

The hope was that giving a potent P2Y12 inhibitor instead of aspirin would reduce platelet aggregation, believed to be a key mediator of graft failure.

Women were older than men, had smaller blood vessels and longer lesions, as well as lengthier procedures and more device-related adverse events.